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Henipaviruses are zoonotic viruses that can cause severe and acute respiratory diseases and encephalitis in humans. To date, no
vaccine or treatments are approved for human use. The presence of neutralizing antibodies is a strong correlate of protection against
lethal disease in animals. However, since RNA viruses are prone to high mutation rates, the possibility that these viruses will escape
neutralization remains a potential concern. In the present study, we generated neutralization-escape mutants, using 6 different
monoclonal antibodies, and studied the effect of these neutralization-escape mutations on in vitro and in vivo ﬁtness. These data
provide a mechanism for overcoming neutralization escape by use of cocktails of cross-neutralizing monoclonal antibodies that rec-
ognize residues within the glycoprotein that are important for virus replication and virulence.
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Henipaviruses (HNVs) are emerging zoonotic viruses that be-
long to the family Paramyxoviridae [1]. The genus Henipavirus
is currently composed of 3 viruses, Hendra virus (HeV), Nipah
virus (NiV), and Cedar virus [2]. Outbreaks of HeV and NiV
infection occur almost yearly in horses and/or humans, and
the human case-fatality rates range from 57%–100% [1]. Cur-
rently, no vaccines or therapeutics are approved for use in
humans. Neutralizing antibodies are a strong correlate of
protection in experimental animal challenge models [3–7]. A
well-characterized human neutralizing monoclonal antibody
(m102.4) has been used on a compassionate-use basis in 9 in-
dividuals who were at high risk of exposure to HeV in Australia
and in 1 individual at high risk of exposure to NiV in the United
States [8]. Several neutralizing monoclonal antibodies (mAbs)
have been described that target the HNV glycoprotein (G)
[8–10].G is a type II transmembrane glycoprotein with a N-ter-
minal cytoplasmic tail, a transmembrane domain, and a C-ter-
minal ectodomain, which is divided into the stalk region and
the globular head domain. The globular head domain is in-
volved in receptor binding, while the stalk region is involved
in triggering the fusion protein (F) to induce virus-cell fusion
[11].The 2 main mechanisms of neutralization involve blocking
the interaction of the HNV G with its receptors ephrin B2 and
B3, to block virus attachment or blocking the induction of
fusion. Recently, the crystal structure of HeV G bound to a de-
rivative of the human mAb m102.4 was solved [12], showing
that the interaction of m102.4 involves binding of 4 hydropho-
bic pockets that also engage the HNV receptors, suggesting di-
rect competition for the receptor-binding site [12].
These data show that neutralizing mAbs are promising can-
didates for prophylactic prevention and treatment of HNV in-
fection. However, the high mutation rates associated with RNA
virus replication also increase concerns about mutations that
confer escape from neutralization. Therefore, it is important
to understand the mechanisms of neutralization escape and
the potential impact on viral ﬁtness.
Here we identiﬁed and characterized several neutralization-
escape mutations generated in vitro with a panel of human
and mouse mAbs and assessed their impact on virulence in
the well-established lethal hamster model.
MATERIALS AND METHODS
Ethics Statement
Approval for animal experiments was obtained from the Uni-
versity of Texas Medical Branch Institutional Animal Care
and Use Committee. Animal work was performed by certiﬁed
staff in an Association for Assessment and Accreditation of
Laboratory Animal Care–approved facility. Animal housing,
care, and experimental protocols were in accordance with Na-
tional Institutes of Health guidelines.
Viruses
HeV, NiV strain Malaysia (NIV-M), and NiV strain Bangladesh
(NiV-B) were kindly provided by the Special Pathogens Branch
(Centers for Disease Control and Prevention, Atlanta, Georgia).
The viruses were propagated on Vero cells (CCL-81; ATCC) as
described previously [13].
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Monoclonal Antibodies and Escape Mutants
A panel of 6 HNV G–speciﬁc mAbs were used in this study.
mAbs against HNVs were generated as described previously
[9, 14]. Mouse mAbs nAH1.3 and 213 were generated against
NiV-M, while mouse mAbs hAH14.2, hAH1.3, and hAH5.1
and human mAb m102.4 were generated against HeV. Neutral-
ization-resistant NiV-M and HeV mutants were generated as
described previously [12].
Neutralization Assay
Neutralizing titers were determined by a plaque reduction neu-
tralization titer (PRNT) assay. For the PRNT, mAbs were seri-
ally diluted 2-fold and incubated with 100 plaque-forming units
(PFU) of NiV-M, NiV-B, or HeV for 1 hour at 37°C. The virus
and antibody mixture was then added to a 6-well plate with
5 × 105 Vero cells/well in triplicate. After incubation for 1
hour at 37°C, cells were overlaid with 3 mL of 0.8% agarose in
medium. Plates were incubated for 3 days at 37°C and stained
with crystal violet in 10% formalin, and plaques were counted.
The percentage of neutralization was calculated as [1 − (num-
ber of plaques with antibody/number of plaques without anti-
body)] × 100. All assays were performed in triplicate.
Structural Mapping of Neutralization-Escape Mutations
The crystal structure coordinates of the HeV and NiV-M
attachment proteins G interacting with their receptor the
human Ephrin B2 (PDB code 2VSK and 2VSM2, respectively)
were used to determine the locations of amino acid residues as-
sociated with neutralization escape [15]. All molecular repre-
sentations were produced with PyMOL (Delano Scientiﬁc).
Virus Growth Curves
Growth curves were performed by inoculating Vero cell cultures
with NiV-M, HeV, and their escape mutants at a low multiplic-
ity of infection (MOI) of 0.01 for 1 hour, after which the cells
were washed 3 times with phosphate-buffered saline and over-
laid with medium. Virus samples were obtained at various time
points after infection and stored at −80°C until viral titers were
determined by a 50% tissue infective culture dose (TCID50)
assay, as previously described [16].
Animal Studies
Female Syrian golden hamsters (Mesocricetus auratus; 6-week-
old HsdHan:AURA hamsters from Harlan Laboratories) were
inoculated with 105 TCID50 of HeV, NiV-M, or their respective
neutralization-escape mutants in a 100-µL volume via the intra-
peritoneal route and were monitored as described previously
[16]. For the pathogenesis study, groups of 5 animals were eu-
thanized on day 3 after infection or when moribund, and
whole-blood samples (collected in Vacutainer tubes containing
ethylenediaminetetraacetic acid), as well as spleen, kidney, lung,
and brain, were removed for virus isolation. Virus titration of
tissue samples was performed as described previously [16].
RESULTS
Identiﬁcation of Amino Acids That Are Critical for HNV Neutralization
mAbs hAH14.2 and hAH1.3 were used for selection of neutral-
ization-escape mutants of HeV, mAbs nAH1.3, hAH5.1 and
213 were used for selection of neutralization-escape mutants
of NiV-M, and mAb m102.4 was previously used to generate
a neutralization-escape mutant of both HeV and NiV-M [12].
Five of 7 escape mutants contained a single amino acid chan-
ge in G, while escape mutants generated by using mAbs hAH5.1
and 213 resulted in 2 amino acid changes each in G (Supple-
mental Table 1). We previously showed that the m102.4 escape
mutants resulted in an amino acid change in NiV-M G at posi-
tion V507I and in HeV G at position D582N [12]. The nAH1.3
escape mutant contained a single amino acid change at position
Q450K in NiV-M G. Interestingly, both mAb hAH5.1 and 213
neutralization-escape mutants contained an amino acid change
at position N159D. In addition to this N159D change, the
hAH5.1 neutralization-escape mutant contained a mutation at
position R516K, whereas the mAb 213 mutant contained a mu-
tation at Q388R. In HeV G, an amino acid change was present at
position H406Y in the hAH14.2 escape mutant. Finally, genera-
tion of neutralization-escape mutants by using the mAb hAH1.3
resulted in an amino acid change at position S134F in HeV G.
Cross-neutralization of Escape Mutants
Unfortunately, hybridomas producing mAbs hAH5.1 and
hAH14.2 used in generating escape mutants were lost owing
to a technical failure during storage. Thus, all further analyses
were performed with mAbs m102.4, nAH1.3, 213, and hAH1.3.
First, the neutralizing antibody titers for each of the mAbs
against HeV, NiV-M, and NiV-B were determined (Figure 1).
mAbs m102.4 and nAH1.3 were able to neutralize HeV and
both NiV-M and NiV-B efﬁciently (Figure 1A and 1B). mAb
213 neutralized NiV-M but not NiV-B or HeV (Figure 1C).
mAb hAH1.3 efﬁciently neutralized HeV but none of the 2
NiV strains (Figure 1D).
Second, we determined whether other mAbs could still neu-
tralize the escape mutants described above (Figures 2 and 3).
Neutralization by mAb m102.4 was only affected by its respec-
tive escape mutations at V507I (NiV-M) and D582N (HeV; Fig-
ures 2A and 3A) and not by mutations generated by other
mAbs. Neutralization by mAb nAH1.3 was affected by its re-
spective NiV-M escape mutant at position Q450K but also by
the mutations at N159D and R516K (Figure 2B), originally gen-
erated by mAb hAH5.1. Interestingly, the mutation at N159D in
combination with a Q388R change did not affect neutralization,
further suggesting that the N159D mutation is not involved in
escape from neutralization. In addition, while mAb nAH1.3 was
generated against NiV G, this antibody also potently neutralized
HeV. Several mutations in HeV G were associated with a de-
crease in neutralization by mAb nAH1.3, including mutations
at positions S134F, H406Y, and D582N (Figure 3B). For mAb
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213, neutralization was not only affected by the virus strain (Fig-
ure 1C) but also by its respective escape mutations N159D and
Q388R (Figure 2C). Again, the N159D mutation in combina-
tion with an R516K change did not result in loss of neutraliza-
tion. Finally, neutralization by hAH1.3 was affected by 3
mutations in HeV G, at positions S134F, H406Y, and D582N,
similar to nAH1.3 (Figure 3C).
Structural Mapping of Amino Acids Critical for Neutralization
To better understand the mechanism of neutralization, the lo-
cation of the amino acid changes associated with neutralization
escape were mapped on the structure of the NiV and HeV
G. Unfortunately, a structure of the stalk region of HeV G (res-
idues 71–188) is not available, and therefore, we were unable to
map the mutation at residue S134. The mutation at residue
H406Y, associated with escape from neutralization by mAb
nAH.3, is located near one of the 4 binding pockets that interact
with residue W122 of ephrin B2 [17] and includes V401 and
N402 on HeV G (Figure 4A). The mutation at D582N is next
to residue Y581, which is part of the binding pocket for the eph-
rin B2 residue F117 (Figure 4A) [17]. The close proximities of
these escape mutations to binding pockets suggest that the
mAbs m102.4 and nAH1.3 and hAH1.3 all neutralize HeV by
interfering with receptor binding.
Two of the mutations associated with escape from neutraliza-
tion of NiV-M (V507I and Q388R) were previously shown to be
important for forming and stabilizing the NiV-M G/ephrin
complex [17, 18]. Residue V507 on the NiV-M G is involved
in van der Waals interactions with residue P122 on ephrin B2
as part of one of the 4 receptor-binding pockets (Figure 4B)
[18], whereas residue Q388 of NiV-M G is part of an intricate
side-chain/side-chain hydrogen bond network that interacts
with residue D108 on ephrin B2 (Figure 4B) [17]. Therefore,
mAb m102.4 and mAb 213 target the receptor-binding domain,
resulting in a direct blockade of the interaction of NiV-M with
its receptors ephrin B2 and B3 as their likely mechanisms of
neutralization. The mutations Q450K and R516K associated
with escape of NiV-M from neutralization by mAb nAH1.3
are located next to each other at the bottom face of the globular
head of NiV-M G, near the stalk domain (Figure 4B). Since this
area is not known to interact with the receptors ephrin B2 or B3,
the mechanism of action remains unknown.
Effect of G Mutations on In Vitro Replication
Since several of the neutralization-escape mutations were locat-
ed in or near the receptor-binding site, we determined whether
these mutations would affect the ﬁtness of these escape mutants
in vitro. The plaque morphology of the wild-type (WT) and
Figure 1. Neutralization of wild-type henipavirus strains. The neutralization of henipaviruses by monoclonal antibodies (mAbs) m102.4 (A), nAH1.3 (B), 213 (C), and hAH1.3
(D) was determined by a plaque reduction neutralization assay. Two Nipah virus (NiV) strains (Malaysia [NiV-M] and Bangladesh [NiV-B]) and 1 Hendra virus (HeV) strain were
used. Neutralization was performed in triplicate and error bars represent the standard deviation.
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neutralization-escape mutants was very similar (data not shown).
All HeV escape mutants grew to similar peak titers and with sim-
ilar kinetics in Vero cells, compared with theWTHeV strain (Fig-
ure 5A). Similarly, all of the NiV-M–derived escape mutants grew
to the same peak titers by 48 hours after infection. However, the
escape mutant containing the N159D/R516K mutations was
signiﬁcantly delayed in replication at 18 hours after infection,
compared with the WT strain (Figure 5B).
Effect of G Mutations on In Vivo Virulence and Replication
Since in vitro replication does not always correlate with in vivo
virulence, we next determined the virulence of the escape
mutants in hamsters. For HeV, mutations in G, associated
Figure 2. Cross-neutralization of Nipah virus (NiV) escape mutants. The neutral-
ization of NiV strain Malaysia (NiV-M) escape mutants by monoclonal antibodies
(mAbs) m102.4 (A), nAH1.3 (B), and 213 (C) was determined by a plaque reduction
neutralization assay. Neutralization was performed in triplicate, and error bars rep-
resent standard deviations. Abbreviation: WT, wild type.
Figure 3. Cross-neutralization of Hendra virus (HeV) escape mutants. The neutral-
ization of HeV escape mutants by monoclonal antibodies (mAbs) m102.4 (A), nAH1.3
(B), and hAH1.3 (C) was determined by a plaque reduction neutralization assay. Neu-
tralization was performed in triplicate, and error bars represent standard deviations.
Abbreviation: WT, wild type.
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with escape from neutralization, did not signiﬁcantly affect
virulence in hamsters. The majority of animals succumbed to dis-
ease around day 6 and 7 (Figure 6A). Interestingly, animals chal-
lenged with the D582Nmutant had a slight delay in time to death
of 8–9 days, and 1 of 5 animals survived (Figure 6C).
While in vitro ﬁtness was not affected by mutations in NiV G
that were associated with neutralization escape, these same
mutations did signiﬁcantly affect the virulence in hamsters.
Hamsters infected with WT NiV-M succumbed to infection
by 3–4 days after challenge (Figure 6B). Interestingly, escape
Figure 4. Structural mapping of escape mutations on the Hendra virus (HeV) and Nipah virus (NiV) attachment glycoprotein (G). The neutralization-escape mutations H406Y
and D582N (A) and Q450K, V507I, and R516K (B) were mapped onto the structures of the HeV (A) and NiV strain Malaysia (NiV-M; B) attachment Gs (in blue), respectively. The
changed amino acid residues are shown in red. The structure of ephrin B2 is shown in yellow. Residues involved in the interaction of G and ephrin B2 are shown as sticks in
orange (on G) and yellow (on ephrin B2).
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mutants with amino acid changes at positions Q388R, Q450K,
or V507I were uniformly lethal but showed a signiﬁcant delay in
their time to death by 8–10 days (Figure 6B and 6D).
Infection of hamsters with WT HeV and NiV resulted in sys-
temic replication of the virus, as previously shown [16]. Infec-
tious HeV and NiV could be detected in brain, lung, spleen, and
kidney, and all animals had evidence of viremia on day 3 after
infection (data not shown). Once animals were moribund, HeV
dissemination of neutralization-escape mutants was similar to
that of the WT strain, with the exception of the D582N muta-
tion, which resulted in lack of dissemination in tissues on day 3
and a complete lack of detectable virus replication in the lung
(Figure 7A). In addition, animals infected with the H406Y
mutant had signiﬁcantly lower levels of virus in the brain
Figure 5. In vitro growth characteristics of wild-type Nipah virus (NiV) and Hendra virus (HeV) and neutralization-escape mutants. Cultures of Vero E6 were infected in
triplicate with wild-type and neutralization-escape mutants of HeV (A) and NiV strain Malaysia (NiV-M; B) at a multiplicity of 0.01, as described in “Materials and Methods”
section. Virus titers at different time points were determined by a 50% tissue infective culture dose (TCID50) assay, using Vero E6 cells. Error bars represent standard deviations.
*P < .05 by 2-way analysis of variance, compared with the wild-type strain.
Figure 6. Effect of neutralization escape on virulence of henipaviruses in hamsters. Time to death (A and B) and percentage survival over time (C and D) for hamsters infected
with wild-type (WT) and neutralization-escape mutants of Hendra virus (HeV; A and C) and Nipah virus strain Malaysia (NiV-M; B and D). Error bars represent standard de-
viations. *P < .05 by 2-way analysis of variance, compared with the WT strain.
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(Figure 7A). Mutations in the NiV-M G at residues Q388R,
V507I, and Q450K resulted in replication below the levels of de-
tection in lungs and brains of moribund hamsters (Figure 7B).
The mutation at R516K resulted in levels of replication in lungs
and brains similar to those for WT NiV-M (Figure 7B).
DISCUSSION
We performed a detailed analysis of the residues critical for
HNV neutralization by 6 different mAbs. We focused on the
G, since this is a major surface membrane glycoprotein that is
required for virus attachment and fusion. As previously report-
ed, mAb m102.4 effectively neutralizes HeV and NiV-M, as well
as the NiV-B strain [12]. Surprisingly, while the mAb 213 efﬁ-
ciently neutralized the NiV-M strain, the NiV-B strain was not
completely neutralized. There are 25 amino acid changes
between the G of NiV-M and NiV-B; however, a mutation at
residue Q388, which was associated with escape from neutrali-
zation by mAb 213, is not one of them. Interestingly, 2 muta-
tions, at residues T385A and K386E, are present in NiV-B,
which could affect the structure of the loop responsible for
the interaction of Q388 with D108 on the ephrin B2 molecule
[18, 19]. It has previously been shown that mAb 213 recognizes
a conformational epitope on the NiV-M G and that binding is
affected by a N-glycosylation site in the stalk region [20].
All neutralization-escape mutations identiﬁed in this study
were detected in the HNV G, and no mutations were present
in F. This is not surprising, since the mAbs used in this study
all targeted the HNVG. Two neutralization-escape mutants had
2 amino acid changes in NiV-M. They shared a mutation at res-
idue N159, but this mutation was unlikely to play a role in neu-
tralization escape, since each escape mutant was only refractory
to neutralization by its respective mAb. This suggests that the
unique changes at R516K or Q388R and not the common
residue at N159D play a role in neutralization escape from
mAbs 213 and nAH1.3. The function of the N159D change
in association with neutralization escape remains unknown,
but it is possible that this is a compensatory change. Position
159 is between 2 critical cysteines, C158 and C162, of the
NiV G stalk region that mediate covalent subunit dimerization
[21]. Residue 159 is also a predicted glycosylation site (G2) that
plays a crucial role in membrane fusion and F triggering [20].
Four of 7 residues associated with escape from neutralization
were near or within the receptor-binding domain located on
the HNV G. The V507I and D582N mutations in NiV-M and
HeV respectively have previously been shown to disrupt m102.4
binding while maintaining high afﬁnity for ephrin B2 and B3. The
crystal structure of m102.3 (m102.4 derivative) bound to the HeV
G shows that m102.3 resembles the G-H loop of ephrin B2 in
both its shape and insertion angle into the HeV G binding pocket
[12]. The HeV escape mutant H406Y is adjacent to another bind-
ing pocket on the HeV G that is responsible for interacting with
the ephrin B2 residue W122 [17]. Finally, the Q388R mutation
affects the hydrogen bond between Q388 and D108 on NiV-M
G and ephrin B2, respectively [18],which imparts afﬁnity and sta-
bilizes the receptor-bound complex [22]. This hydrogen bond is
involved in an area that contains salt bridges and other hydrogen
bonds. The Q388R mutation is close to the T385A and K386E
found on the NiV-B strain, which could explain why the NiV-B
strain is not efﬁciently neutralized by mAb 213. Interestingly, this
epitope is also missing in a recently described HNV isolated from
a Ghanaian bat, suggesting that this virus would not be suscepti-
ble to neutralization by mAb 213 [22, 23].
It should be noted that the neutralization-escape mutants in
the current study were generated under artiﬁcial conditions.
Since viral proteins can undergo conformational changes under
different physiological conditions, the ability or kinetics by
Figure 7. Effect of neutralization escape on replication of henipaviruses in hamsters. Lung (black bar) and brain (white bar) titer results for hamsters infected with wild-type
(WT) and neutralization-escape mutants of Hendra virus (HeV; A) and Nipah virus strain Malaysia (NiV-M; B) when moribund. Lung and brain tissues were harvested from
infected hamsters when moribund and were assayed for infectious virus as described in “Materials and Methods” section. Tissue samples from 5 animals were analyzed. Error
bars represent standard deviations. *P < .05 by 2-way analysis of variance, compared with the WT strain.
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which amAb binds G can be dependent on the environment [24].
This could potentially affect the escape variants that arise, and
therefore it would be interesting compare neutralization-escape
mutants that were generated in vitro with those generated in vivo.
We have previously shown that escape from neutralization
can be associated with reduced viral ﬁtness [25]. Several neutral-
ization-escape mutations in the receptor-binding domain of
SARS coronavirus resulted in reduced replication in a variety
of cells and reduced virulence in mice [25]. In the current
study, several amino acids associated with neutralization escape
were previously shown to be directly involved in binding to the
receptor ephrin B2. In a more recent study, we have shown that
mutations at V507 and D582 on the NiV-M and HeV G, respec-
tively, did not result in signiﬁcant differences in replication in
vitro [12]. Here we expanded this ﬁnding by testing the in
vitro replication of 5 other neutralization-escape mutants. Al-
though at least 2 of these mutations were located within the
receptor-binding domain, no changes in propagation were
detected, but a change at R516K resulted in a lower titer at
18 hours after infection, suggesting that entry may have been af-
fected by this mutation. While virus replication was not affected
in cell culture, signiﬁcant attenuation was observed for some
mutants in the hamster model. Several neutralization-escape
mutations in NiV-M G resulted in a signiﬁcant delay in time
to death (4–6 days). In addition, a reduction in virus titers
was observed in lung and brain tissues, considered key target
organs for HNV infection in hamsters [16].
The development of neutralization-escape mutants that are
not affected in their in vitro and in vivo replication is a potential
concern for the further development of neutralizing mAbs for
treatment or prophylaxis. However, treatment of nonhuman
primates with m102.4 up to 5 days after infection has complete-
ly protected against lethal infection with NiV-M or HeV, and no
evidence has been found for the emergence of a neutralization-
escape mutant in this model [6, 26].
In conclusion, we have characterized several mAbs that recog-
nize distinct epitopes on the HNV G. Several of these mAbs target
epitopes that are directly involved in receptor binding and thus
likely inhibit this crucial ﬁrst step of virus infection. A cocktail of
these mAbs may be preferential to a single mAb, given the fact that
escape from neutralization can occur without affecting virulence.
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